OCUL - Company ID 0001393434
The table below shows OCULAR THERAPEUTIX, INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $51.95M | $63.72M | $58.44M | $51.49M | $43.52M | $17.40M |
| Cost of revenue | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M | $2.08M |
| Gross profit | - | - | - | - | - | - |
| R&D | $197.10M | $127.64M | $61.05M | $53.46M | $50.08M | $28.69M |
| SG&A |
OCULAR THERAPEUTIX, INC reported annual revenue of $51.95M for fiscal year 2025. That is down 18.5% from $63.72M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.89M (FY 2016) to $51.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $64.38M |
| $60.65M |
| $33.94M |
| $32.22M |
| $31.88M |
| $22.86M |
| Operating income | -$270.02M | -$171.78M | -$82.38M | -$78.65M | -$78.04M | -$62.85M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$265.94M | -$193.51M | -$80.74M | -$71.04M | -$6.55M | -$155.64M |
| EPS (diluted) | -$1.42 | -$1.22 | -$1.02 | -$0.97 | -$0.98 | -$2.56 |